May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Focal Laser Photocoagulation Facilitated by Previous Intravitreal Triamcinolone in Eyes With Clinically Significant Diabetic Macular Edema: 6 Months Results
Author Affiliations & Notes
  • M. Timmermann
    Augenzentrum Klinik Pallas, Olten, Switzerland
  • J. Riese
    Augenzentrum Klinik Pallas, Olten, Switzerland
  • V. Loukopoulos
    Augenzentrum Klinik Pallas, Olten, Switzerland
  • C. Meier
    Augenzentrum Klinik Pallas, Olten, Switzerland
  • H. Gerding
    Augenzentrum Klinik Pallas, Olten, Switzerland
  • Footnotes
    Commercial Relationships  M. Timmermann, None; J. Riese, None; V. Loukopoulos, None; C. Meier, None; H. Gerding, Novartis, R.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3477. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Timmermann, J. Riese, V. Loukopoulos, C. Meier, H. Gerding; Focal Laser Photocoagulation Facilitated by Previous Intravitreal Triamcinolone in Eyes With Clinically Significant Diabetic Macular Edema: 6 Months Results. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3477. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To perform a 6 months interim analysis on the development of visual acuity, OCT central foveal thickness, and fluorescence angiographic findings after combined intravitreal triamcinolone (4 mg) and focal laser photocoagulation in eyes with clinically significant diabetic macular edema.

Methods: : Retrospective analysis of 47 eyes (47 patients, mean age 68 +/- 9.5 years) with persistent macular edema due to diabetic retinopathy. Patients received an intravitreal injection of 4 mg triamcinolone and laser coagulation (dense focal grid coagulation) after subsequent remission of edema within the previously edematous area. 26 patients received 1, 15 patients 2, 7 patients 3, 3 patients 4, and 1 patient 5 sessions of laser treatment after the first injection of triamcinolone. The first laser application was performed at a median of 18 days after triamcinolone injection (range: 14 - 70 days). Standardized clinical examinations were including best corrected visual acuity testing, anterior and posterior segment biomicroscopy, IOP, and OCT before triamcinolone injection and at day 1, after 1 week, 2 weeks, 1 month, 2 months, 3 months and 6 months postoperatively. Fluorescein angiography was performed before triamcinolone injection and 3 and 6 months later. 3 patients received a second injection and photocoagulation at 3 months and 8 patients at 6 months, respectively.

Results: : Mean visual acuity improved from baseline 0.32 (+/- 0.17, n=47) to 0.36 (+/- 0.24, n=44, p<0.025) after 1 month, 0.38 (+/- 0.22, n=41, p<0.05) after 3 months, and 0.41 (+/- 0.21, n=30, p<0.05) after 6 months. OCT-central foveal thickness of preoperatively 421µm (+/- 112) decreased to 309µm (+/- 75) at 1 month (n=32, p<0.00025), 324µm (+/- 96) at 3 months (n=32, p<0.001), and 352µm (+/- 123) after 6 months (n=25, p<0.05). In all cases a significant reduction of macular and foveal edema was observed at 3 and 6 months follow-up fluorescence angiography. 28% of the patients developed a secondary ocular hypertension which was controlled by local therapy

Conclusions: : According to these previous results a combination of intravitreal triamcinolone injection and subsequent laser photocoagulation is an effective treatment for cases with clinically significant diabetic macular edema. Contrary to previous strategies, triamcinolone offers a better approach to photocoagulation of diseased retinal areas during the time period of edema regression.

Keywords: diabetic retinopathy • macula/fovea • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×